Lab
Marlboro Chesterfield Pathology, PC
Marlboro Chesterfield Pathology, PC was paid $2.07M by Medicaid between Jan 2018 and Dec 2024, across 18 billing codes. Its largest line is 88305, Level IV - Surgical pathology, gross and microscopic examination — 24% of everything it billed.
33Billing provider infoMARLBORO CHESTERFIELD PATHOLOGY, PC
PINEHURST, NC 28374
PINEHURST, NC 28374
33aNPI1619953965assigned 12/19/2005
33bProvider typeClinical Medical Laboratory
28Total paid$2.07M
24GClaims60,945
24DCodes billed18
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in North Carolina
Rank by total paid#35 of 128
Median peer was paid$268K
This provider vs. median7.7×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 9,335 | $328K | |
| 2019 | 11,253 | $350K | |
| 2020 | 10,374 | $368K | |
| 2021 | 11,861 | $423K | |
| 2022 | 7,704 | $267K | |
| 2023 | 6,324 | $186K | |
| 2024incomplete | 4,094 | $149K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 24% | 6,739 | 5,897 | $500K |
| 88342 | 19% | 9,360 | 6,996 | $398K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 14% | 10,699 | 9,481 | $291K |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | 14% | 10,378 | 8,995 | $289K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 14% | 10,673 | 9,442 | $288K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | 5.2% | 4,310 | 3,943 | $107K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | 3.9% | 3,106 | 2,696 | $81K |
| 88141 | 2.8% | 3,089 | 2,663 | $58K | |
| 88312 | <1% | 300 | 268 | $17K | |
| 88313 | <1% | 306 | 278 | $12K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 546 | 485 | $11K |
| 87481 | <1% | 403 | 183 | $4K |
6 more codes
| 88112 | <1% | 152 | $4K | |
| 87511 | <1% | 202 | $4K | |
| 88341 | <1% | 47 | $3K | |
| 88344 | <1% | 27 | $2K | |
| 87800 | <1% | 70 | $2K | |
| G9785 | Pathology report diagnosing cutaneous basal cell carcinoma, squamous cell carcinoma, or melanoma (to include in situ disease) sent from the pathologist/ dermatopathologist to the biopsying clinician for review within 7 days from the time when the tissue specimen was received by the pathologist | 0% | 538 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialDEMBOSKY, DELL (OWNER)